Pharma Alert | BMS’ apixaban patent upheld in merits proceedings against Sandoz and Teva
Sandoz’ and Teva’s invalidity arguments were dismissed and an injunction against Sandoz was awarded.
Publications & Blogs
Amsterdam court confirms €7.5 million fine for Pharmathen for patent infringement
In a case of Novartis against Pharmathen, the Amsterdam Court of Appeal confirmed on 26 March 2024 that Pharmathen will have to pay EUR 7,500,000 in fines for breach of an injunction which had been imposed for patent infringement.
Pharma Alert | Novartis/Pharmathen decision confirmed on appeal
Pharma Alert | Apixaban decision overturned on appeal: injunction granted
By judgment of 15 August 2023 in PI proceedings brought by Bristol-Myers Squibb, the Court of Appeal of The Hague prohibited Sandoz, Stada and Teva from marketing generic apixaban.
Unified Patent Court nears, Opt-out or not?
The Unified Patent Court has the potential to change a lot about how inventions are protected in European patent practice. The UPC brings both certainty and uncertainty and has advantages, but certainly also disadvantages.
State of the Art
In ‘State of the Art’, our lawyers from the IP & Technology practice group share their expertise on the main themes and current developments within information law.
Telecoms update | District Court rejects PI in SEP Infringement proceedings against Oppo distributors
By decision of 11 January 2023, the District Court of The Hague (the Court) rejected Nokia’s claim for a preliminary injunction against Oleading B.V. and Reflection Investment B.V. (Oppo Distributors) regarding the alleged infringement of Standard Essential Patents (SEPs).
Telecoms update | District Court rejects Orope’s invalidity claims against two SEPs of Nokia
On 7 September 2022, the District Court of The Hague (“the Court”) rendered judgment in two final relief proceedings between Orope Germany GmbH (“Orope Germany”) and Nokia Solutions and Networks OY (“Nokia”) regarding the alleged invalidity of two of Nokia’s SEPs.
Pharma update | Fingolimod Preliminary Injunction also rejected in Appeal
The Court of Appeal of The Hague affirms the first instance decision in which the PI judge of the District Court rejected Novartis’ claim for a preliminary injunction against Mylan.
Pharma update | PI judge holds fingolimod 0.5 mg patent provisionally invalid
In its interim relief decision of 21 June 2022 the PI Judge of the District Court of The Hague held Novartis’ EP 2 959 894 (“EP 894”) re fingolimod 0.5 mg provisionally invalid. This is the first substantive PI decision on this matter in Europa, where several proceedings between Novartis and Mylan are pending.
Pharma update | Apixaban patent and SPC provisionally held invalid
In its decision of 10 May 2022 in PI proceedings between Bristol-Myers Squibb Holdings Ireland Unlimited Company (“BMS”) and Sandoz B.V. (“Sandoz”), the PI judge of the District Court of The Hague denied BMS’ claim for injunctive relief regarding the sale of generic apixaban by Sandoz. According to the Judge, there is no inventive step due to lack of plausibility and therefore a good chance that the patent (and the SPC) will be held invalid in final relief proceedings.
Court finds Mammoet’s press release unlawful
Huisman had issued a press announcement that it had concluded an agreement with BMW for the design and construction of a so-called “ringer crane”. Following Huisman’s press statement, Mammoet issued a press release entitled “Mammoet starts investigation of patent infringement by Huisman and BMS”, in which it refers to the ringer crane to be built by Huisman. Huisman sued Mammoet, arguing that the suggestion that Huisman was committing patent infringement was unlawful. The Provisions Judge of the District Court in…